

Myeloma				
Cohort Studies	Supportive Care	Relapsed	1 <sup>st</sup> Line Treatment	
<p>FAB-IE (O A)</p> <p>NCRN443/PREAMBLE (O I)</p> <p>MMTA (O I)</p> <p>Osteoclasto-genic properties of MM cells (O A)</p> <p>DNA Damage Repair Defects (O A)</p> <p>DJIM (O A)</p> <p>CANC 3619 (O I)</p>	<p>TEAMM (D A)</p> <p>NCRN436 (O I)</p> <p>MyCare (O A)</p> <p>MM lifestyle study (O P)</p> <p>NCRN 2961 (O I)</p> <p>ACUFOCIN</p>	<p>CANC 3616: AFFIRM (O I)</p> <p>LenaRIC (Transplant) (D A)</p> <p>NCRN 630 (O I)</p> <p>NCRN2629 (O I)</p> <p>MUK Three (D P)</p> <p>MUK Five (D A)</p> <p>MUK Seven (D A)</p> <p>NCRN396/VE BASKET (O I)</p> <p>NCRN491: PANORAMA-3 (O I)</p> <p>Bubble (D A)</p>	<p>Myeloma XI (D P)</p> <p>NCRN 269 (O I)</p> <p>OPTIMAL (D P)</p> <p>CANC 3935 (O I)</p> <p>CANC 3527 (O I)</p> <p>CARDAMON (C I)</p>	<p>CANC – 3527: Oral ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation</p> <p>CANC – 3616: Filanesib (ARRY-520) in pts with advanced MM</p> <p>CANC – 3619: Post authorisation registry of pts treated with pomalidomide for relapsed/refractory MM who received at least two prior treatment regimens, including lenalidomide and bortezomib, and demonstrated disease progression on last therapy</p> <p>CANC – 3935: VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP)</p> <p>NCRN 269: Siltuximab (Anti-IL-6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma</p> <p>NCRN 396/ VE BASKET: vemurafenib in patients with BRAF V600 mutation-positive cancers</p> <p>NCRN 436: Safety, immunogenicity &amp; efficacy of GSK Biologicals Herpes Zoster HZ/su candidate vaccine</p> <p>NCRN 443/PREAMBLE: Prospective research assessment in Multiple Myeloma</p> <p>NCRN 491/PANORAMA-3: Pharmacokinetics &amp; safety of oral panobinostat + dexamethasone and subcutaneous (SC) or intravenous (IV) administration of bortezomib</p> <p>NCRN 630: ExAblate vs External Beam Radiation in Bone Tumours &amp; Multiple Myeloma</p> <p>NCRN – 2629: Pomalidomide with low-dose dexamethasone in Multiple Myeloma</p> <p>NCRN – 2961: Oral Ixazomib Citrate (MLN9708) Maintenance Therapy Following Autologous Stem Cell Transplant</p>